Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

Virology

Volumn 383, Issue 2, 2009, Pages 348-361

  Bukreyev, Alexander ^a   Marzi, Andrea ^b   Feldmann, Friederike ^b   Zhang, Liqun ^d   Yang, Lijuan ^a   Ward, Jerrold M ^a   Dorward, David W ^e   Pickles, Raymond J ^d   Murphy, Brian R ^a   Feldmann, Heinz ^b,c   Collins, Peter L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Public Health Agency of Canada   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antibody; Ebola virus; Vaccine; Vector

Indexed keywords

F PROTEIN; HN PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; NONHUMAN; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; VIROGENESIS; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; BLOOD; BODY WEIGHT; CELL LINE; CERCOPITHECUS AETHIOPS; EBOLA VACCINES; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LUNG; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR SEQUENCE DATA; ORGAN CULTURE TECHNIQUES; PARAINFLUENZA VIRUS 3, HUMAN; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRION;

ANIMALIA; CAVIA; EBOLA VIRUS; HUMAN PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS;

EID: 58149129187     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.09.030     Document Type: Article

References (44)

1. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., and Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172 10 (2004) 6290-6297
2. Bukreyev A., Yang L., Zaki S.R., Shieh W.J., Rollin P.E., Murphy B.R., Collins P.L., and Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80 5 (2006) 2267-2279
3. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., Murphy B.R., Collins P.L., and Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81 12 (2007) 6379-6388
4. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K.A., Dubey S., Zhu D.M., Nawrocki D., Mach H., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith J.G., Wang S., Liu X., Guan L., Long R., Trigona W., Heidecker G.J., Perry H.C., Persaud N., Toner T.J., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B., Emini E.A., and Shiver J.W. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77 11 (2003) 6305-6313
5. Collins P.L., and Bukreyev A. Advances in the development of vaccines against Marburg and Ebola viruses. Future Virology 2 6 (2007) 537-541
6. Collins P.L., and Crowe J.E.J. Respiratory syncytial virus and metapneumovirus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). "Fields Virology". 5 ed Vol. 2 (2007), Lippincott-Raven Publishers, Philadelphia 1601-1646 2 vols.
7. Connolly B.M., Steele K.E., Davis K.J., Geisbert T.W., Kell W.M., Jaax N.K., and Jahrling P.B. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179 Suppl. 1 (1999) S203-S217
8. Durbin A.P., Skiadopoulos M.H., McAuliffe J.M., Riggs J.M., Surman S.R., Collins P.L., and Murphy B.R. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J. Virol. 74 15 (2000) 6821-6831
9. Elango N., Coligan J.E., Jambou R.C., and Venkatesan S. Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein. J. Virol. 57 2 (1986) 481-489
10. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., Giles-Davis W., Wilson J.M., and Ertl H.C. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170 3 (2003) 1416-1422
11. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., Volchkov V., Klenk H.D., Feldmann H., and Stroher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78 10 (2004) 5458-5465
12. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 Suppl. 12 (2004) S110-121
13. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., and Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8 5 (2002) 503-507
14. Jaax N., Jahrling P., Geisbert T., Geisbert J., Steele K., McKee K., Nagley D., Johnson E., Jaax G., and Peters C. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346 8991-8992 (1995) 1669-1671
15. Jaax N.K., Davis K.J., Geisbert T.J., Vogel P., Jaax G.P., Topper M., and Jahrling P.B. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 120 2 (1996) 140-155
16. Jahrling P.B. Filoviruses and arenaviruses. In: Murray P.R. (Ed). Manual of Clinical Microbiology (1999), ASM Press, Washington, D.C. 1125-1136
17. Johnson E., Jaax N., White J., and Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76 4 (1995) 227-236
18. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., and Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 7 (2005) 786-790
19. Jones S.M., Stroher U., Fernando L., Qiu X., Alimonti J., Melito P., Bray M., Klenk H.D., and Feldmann H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J. Infect. Dis. 196 Suppl. 2 (2007) S404-S412
20. Kanesa-Thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I., Tang D.B., Vaughn D.W., Mason P.W., and Shope R.E. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19 4-5 (2000) 483-491
21. Karron R.A., and Collins P.L. "Parainfluenza viruses.". In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5 ed. 1. 2 vols. (2007), Lippincott-Raven Publishers, Philadelphia
22. Kolakofsky D., Pelet T., Garcin D., Hausmann S., Curran J., and Roux L. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J. Virol. 72 2 (1998) 891-899
23. Kolesnikova L., Ryabchikova E., Shestopalov A., and Becker S. Basolateral budding of Marburg virus: VP40 retargets viral glycoprotein GP to the basolateral surface. J. Infect. Dis. 196 Suppl 2 (2007) S232-S236
24. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., Nanda A., Ewald B.A., Gorgone D.A., Lifton M.A., Goudsmit J., Havenga M.J., and Barouch D.H. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 79 15 (2005) 9694-9701
25. Pickles R.J., McCarty D., Matsui H., Hart P.J., Randell S.H., and Boucher R.C. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72 7 (1998) 6014-6023
26. Sanchez A., Kiley M.P., Holloway B.P., and Auperin D.D. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 29 3 (1993) 215-240
27. Sanchez A., Trappier S.G., Mahy B.W., Peters C.J., and Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U. S. A. 93 8 (1996) 3602-3607
28. Sanchez A., Geisbert T.W., and Feldmann H. "Filoviridae: Marburg and Ebola viruses.". In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5 ed. 1. 2 vols. (2007), Lippincott-Raven Publishers, Philadelphia
29. Sanger C., Muhlberger E., Ryabchikova E., Kolesnikova L., Klenk H.D., and Becker S. Sorting of Marburg virus surface protein and virus release take place at opposite surfaces of infected polarized epithelial cells. J. Virol. 75 3 (2001) 1274-1283
30. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., Hirsch V., and Cranage M. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82 Pt 9 (2001) 2215-2223
31. Spriggs M.K., Olmsted R.A., Venkatesan S., Coligan J.E., and Collins P.L. Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. Virology 152 1 (1986) 241-251
32. Storey D.G., Dimock K., and Kang C.Y. Structural characterization of virion proteins and genomic RNA of human parainfluenza virus 3. J. Virol. 52 3 (1984) 761-766
33. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., Lifton M.A., Koudstaal W., Pau M.G., Kostense S., Havenga M.J., Goudsmit J., Letvin N.L., and Barouch D.H. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78 6 (2004) 2666-2673
34. Tao T., Skiadopoulos M.H., Davoodi F., Riggs J.M., Collins P.L., and Murphy B.R. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J. Virol. 74 14 (2000) 6448-6458
35. Tashiro M., Seto J.T., Choosakul S., Yamakawa M., Klenk H.D., and Rott R. Budding site of Sendai virus in polarized epithelial cells is one of the determinants for tropism and pathogenicity in mice. Virology 187 2 (1992) 413-422
36. van Wyke Coelingh K.L., Winter C., and Murphy B.R. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 143 2 (1985) 569-582
37. Volchkov V.E., Becker S., Volchkova V.A., Ternovoj V.A., Kotov A.N., Netesov S.V., and Klenk H.D. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214 2 (1995) 421-430
38. Volchkov V.E., Chepurnov A.A., Volchkova V.A., Ternovoj V.A., and Klenk H.D. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277 1 (2000) 147-155
39. Wechsler S.L., Lambert D.M., Galinski M.S., and Pons M.W. Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides. J. Virol. 54 3 (1985) 661-664
40. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., Yang Z.Y., Dell A., Haslam S.M., Wilson I.A., and Nabel G.J. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82 13 (2008) 6200-6208
41. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77 1 (2003) 799-803
42. Yang L., Sanchez A., Ward J.M., Murphy B.R., Collins P.L., and Bukreyev A. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 377 2 (2008) 255-264
43. Zhang L., Bukreyev A., Thompson C.I., Watson B., Peeples M.E., Collins P.L., and Pickles R.J. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol. 79 2 (2005) 1113-1124
44. Zhi Y., Figueredo J., Kobinger G.P., Hagan H., Calcedo R., Miller J.R., Gao G., and Wilson J.M. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum. Gene Ther. 17 5 (2006) 500-506